Monday, June 24, 2024
Insulet Corporation has launched Omnipod 5 in the U.K. and the Netherlands, marking a milestone for diabetes care.
Omnipod 5 is an automated insulin delivery (AID) system that integrates with Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor (CGM) sensors, making it the first tubeless system to offer such compatibility.
This advancement provides greater flexibility for individuals aged two years and older with type 1 diabetes.
Insulet's Senior Vice President and International General Manager, emphasized the significance of expanding global access to Omnipod 5.
Highlighted the system's ability to deliver tubeless AID without requiring a change in CGM sensor brand, which represents a major improvement in diabetes management.
Omnipod 5 features a tubeless, waterproof design with proactive glucose control capabilities, designed to enhance user convenience and effectiveness. Clinical studies have shown improvements in A1c levels and increased time within target glucose ranges, while reducing time spent in hypoglycemia.
18-year-old student from the Netherlands living with type 1 diabetes, shared his positive experience with Omnipod 5, noting its transformative impact on his daily life by effortlessly maintaining his blood sugar levels within the desired range.
The integration of Omnipod 5 with Dexcom G6 and Abbott FreeStyle Libre 2 Plus sensors allows healthcare providers to choose the most suitable CGM sensor for their patients, simplifying the adoption of AID therapy.
Type 1 Diabetes and Technology Lead at NHS England, expressed optimism about the expanded accessibility of Omnipod 5 with the FreeStyle Libre 2 Plus sensor. Underscored the potential of this advancement to significantly simplify diabetes management and improve outcomes for individuals across the U.K. and the Netherlands.
In summary, the launch of Omnipod 5 with dual sensor integration represents a significant advancement in diabetes care technology, offering enhanced freedom and efficacy in insulin delivery for individuals with type 1 diabetes.
Source: businesswire.com
